740129
Last Update Posted: 2021-05-26
Recruiting has ended
All Genders accepted | Under |
6 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Re-treatment of Participants With Paget's Disease Using Zoledronic Acid
The purpose of this study was to demonstrate that participants with Paget's disease of the bone who had responded to zoledronic acid treatment as participants in the core registration studies CZOL446K2304 and CZOL446K2305 and later experienced a relapse can be successfully treated with a 5 milligram (mg) infusion of zoledronic acid.
Uncontrolled study
Eligibility
Relevant conditions:
Paget's Disease of the Bone
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov